Remus Pharmaceuticals (NSE:REMUS) Total Operating Expense: ₹575 Mil (TTM As of Mar. 2026)


NSE:REMUS Remus Pharmaceuticals Ltd NSE:REMUS
55 GF Score
Price ₹758.80
GF Value ₹2,071.36
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Remus Pharmaceuticals Total Operating Expense?

Remus Pharmaceuticals NSE:REMUS -2.72% 55 Total Operating Expense is ₹575 Mil as of Mar. 2026. GuruFocus rates NSE:REMUS with a GF Score™ of 55/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Remus Pharmaceuticals's Total Operating Expense for the six months ended in Mar. 2026 was ₹325 Mil. Remus Pharmaceuticals's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was ₹575 Mil.

Remus Pharmaceuticals Total Operating Expense Related Terms

Remus Pharmaceuticals Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Remus Pharmaceuticals's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Remus Pharmaceuticals Total Operating Expense Chart

Remus Pharmaceuticals Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Operating Expense
Get a 7-Day Free Trial 83.37 0.00 190.70 436.70 575.00

Remus Pharmaceuticals Semi-Annual Data
Mar20 Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only 124.75 206.80 229.90 250.40 324.60
NSE:REMUS
55GF Score
Remus Pharmaceuticals Ltd NSE:REMUS
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Remus Pharmaceuticals Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹575 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of ₹575 Mil mean?
Remus Pharmaceuticals (NSE:REMUS) has a Total Operating Expense of ₹575 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Remus Pharmaceuticals and its competitors.
Is Remus Pharmaceuticals' Total Operating Expense too high?
Remus Pharmaceuticals' current Total Operating Expense is ₹575 Mil. Overall, Remus Pharmaceuticals has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' Total Operating Expense compare to MCK and CAH?
Remus Pharmaceuticals' Total Operating Expense of ₹575 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Medical Distribution company?
A good Total Operating Expense depends on the Medical Distribution industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Remus Pharmaceuticals and its competitors. Remus Pharmaceuticals's current Total Operating Expense is ₹575 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹758.80 — trading 63.4% below its estimated fair value. The current Total Operating Expense is ₹575 Mil. Remus Pharmaceuticals' overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current Total Operating Expense is ₹575 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?

Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued. The current stock price of ₹758.80 is trading 63.4% below its estimated GF Value™ of ₹2,071.36. GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for NSE:REMUS:

  • Total Operating Expense: ₹575 Mil
  • GF Value™: ₹2,071.36 vs. price of ₹758.80 (63.4% below fair value)
  • GF Score™: 55/100 with 2 warning signs

No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Remus Pharmaceuticals Business Description

Address Ambli bopal Road, 1101 to 1103, South Tower, One 42, Behind Ashok Vatika, Near Jayantilal Park BRTS, Ahmedabad, GJ, IND, 380054
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
55GF Score

Get the complete analysis for NSE:REMUS

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹758.80
Price
₹2,071.36
GF Value